Vascular Endothelial Protection Effects of Dextromethorphan
Anti-Inflammation & Vascular Endothelial Protection Effects of Dextromethorphan on Heavy Smoker
研究概览
详细说明
Dextromethorphan (DM), an ingredient widely used in antitussive remedies, had been reported to reduce the inflammation-mediated degeneration of neurons. We recently found that DM can prevent vascular remodeling and neuron injury in animal models of carotid ligation and cerebral ischemia injuries, respectively. It was believed that its action was through the anti-oxidant and NADPH pathway to protect brain cells. However, the mechanism and actual effect on human vascular protection remained unclear.
To test the hypothesis that DM could have anti-inflammatory effect and thus achieve vascular protection effect on heavy smokers, this prospective study will be conducted to treat subjects with heavy smoking history with DM or not and evaluate the anti-inflammatory and the improvement of endothelial function.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- healthy male volunteers who are currently smoking
Exclusion Criteria:
- personal history of hypertension or diabetes mellitus
- family history with
- documented premature cardiovascular events
- cardiovascular-associated sudden death
- total cholesterol > 240 mg/dL
- triglyceride > 200 mg/dL
- low-density lipoprotein > 160 mg/dL.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:1个
|
120 mg/day, single once daily dose taken after breakfast by oral route
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Endothelial function
大体时间:1, 2, 3 and 6 month
|
1, 2, 3 and 6 month
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Surrogate end-points of the study: hs-CRP, sPLA2, matrix metalloproteinase-3, interleukin-6, tumor necrosis factor-alfa receptor II, GSH-Px, and urinary excretion of 8-PGF2alfa
大体时间:1, 2, 3 and 6 months
|
1, 2, 3 and 6 months
|
合作者和调查者
调查人员
- 首席研究员:Ping-Yen Liu, MD, PhD、Assiatant Professor of National Cheng Kung University Medical Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.